Global Cancer Monoclonal Antibodies Market- New Research Report Announced with business priorities in order to assist companies to realign their business strategies.
City of Industry, CA -- (SBWIRE) -- 07/14/2018 -- This report studies the global Cancer Monoclonal Antibodies market status and forecast, categorizes the global Cancer Monoclonal Antibodies market size (value & volume) by key players, type, application, and region. This report focuses on the top players in North America, Europe, China, Japan, Southeast Asia India and Other regions (Middle East & Africa, Central & South America).
The mAbs, which are produced by genetic engineering, target antigens in cells, tissues, and organs. They are used in clinical applications to treat diseases with excellent efficacy and minimal side effects. Their MOA, absence of generic pathway, and therapeutic applications distinguish them from other targeted therapeutics.
Request Sample Copy of the Report @ https://www.qyresearch.com/sample-form/form/582734/global-cancer-monoclonal-antibodies-sales-market
Cancer is one of the leading causes of death globally. There were 10.9 million new cases, in 2002, which increased to 14.1 million, in 2012 (approximately 30% growth in a decade). The WHO expects this number to increase by 70%, over the next two decades. According to the WHO, almost 70% of deaths occur in low and middle-income countries. The increment in data is expected to provide the basis for any national policy on cancer, leading to an increase in the percentage of people choosing cancer treatment. In the healthcare sector, cancer is one of the biggest concerns. Thus, the increased use of monoclonal antibodies for the treatment of cancer is driving this market.
Monoclonal Antibodies having the potential to offer less toxic and efficient therapeutic alternatives to the patients have been emerging in the recent years. Monoclonal Antibodies are used to treat a wide array of diseases related to autoimmune, inflammatory and especially cancer. Monoclonal Antibodies (mAbs) are mono-specific antibodies bodies comprising of identical immune cells that are clones of a single parent cells and are directed to a specific cellular targets. Thus Monoclonal Antibodies are highly customizable due to its specific nature and can play a crucial role in eliminating the cancerous cell while sparing the normal cells during the cancer treatment. The monoclonal antibodies are proved to be more effective than chemotherapies and drugs for cancer treatment.
The global Cancer Monoclonal Antibodies market is valued at xx million US$ in 2017 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2018-2025.
Ask for Discount on Research Report@ https://www.qyresearch.com/request-discount/form/582734/global-cancer-monoclonal-antibodies-sales-market
The major players covered in this report
F. Hoffmann-La Roche
Geographically, this report studies the key regions, focuses on product sales, value, market share and growth opportunity in these regions, covering
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
Chimeric and Humanised Antibodies
Fully Humanized Antibodies
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
Hodgkins and Non-Hodgkins lymphoma
Click to view the full report TOC, figure and tables: https://www.qyresearch.com/index/detail/582734/global-cancer-monoclonal-antibodies-sales-market
About QY Research
QY Research established in 2007, focus on custom research, management consulting, IPO consulting, industry chain research, data base and seminar services. The company owned a large basic data base (such as National Bureau of statistics database, Customs import and export database, Industry Association Database etc), expert's resources (included energy automotive chemical medical ICT consumer goods etc.